Human LAP (TGF-beta 1) Antibody
R&D Systems, part of Bio-Techne | Catalog # AB-246-NA
Scientific images may be resized, cropped, or adjusted for brightness or contrast for presentation purposes. These updates are limited to presentation and do not affect the underlying scientific interpretation of the data. Where available, additional source data may be provided upon request.
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human, Mouse
Applications
Validated:
Immunohistochemistry, Western Blot, Neutralization, Immunocytochemistry
Cited:
Immunohistochemistry, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Western Blot, Neutralization
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Product Specifications
Immunogen
S. frugiperda insect ovarian cell line Sf 21-derived recombinant human LAP (TGF-beta 1) and Chinese hamster ovary cell line CHO-derived recombinant human LAP (TGF-beta 1)
Leu30-Ser390
Accession # P01137
Leu30-Ser390
Accession # P01137
Specificity
Detects human LAP in direct ELISAs and Western blots. In direct ELISAs and Western blots, this antibody is specific for the LAP derived from the TGF-beta 1 precursor but does not react with LAP from the TGF-beta 2 precursor.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human LAP (TGF-beta 1) Antibody
TGF-beta 1 in Human PBMCs.
TGF-beta 1 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using Goat Anti-Human LAP TGF-beta 1 Polyclonal Antibody (Catalog # AB-246-NA) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (yellow; Catalog # NL001) and counter-stained with DAPI (blue).View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
LAP TGF‑ beta1 Inhibition of TGF‑ beta1 Activity and Neutralization by Human LAP TGF‑ beta1 Antibody.
Recombinant Human LAP TGF-beta 1 (Catalog # 246-LP) inhibits Recombinant Human TGF-beta 1 (Catalog # 240-B) growth inhibition activity in the HT-2 mouse T cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human TGF-beta 1 (0.25 ng/mL) activity elicited by Recombinant Human LAP TGF-beta 1 (125 ng/mL) is neutral-ized (green line) by increasing concentrations of Goat Anti-Human LAP TGF-beta 1 Polyclonal Antibody (Catalog # AB-246-NA). The ND50 is typically 15-30 µg/mL.
LAP (TGF-beta 1) in Human Prostate Cancer Tissue.
LAP (TGF-beta 1) was detected in immersion fixed paraffin-embedded sections of human prostate cancer tissue using Goat Anti-Human LAP (TGF-beta 1) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-246-NA) at 10 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm in epithelial cells. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.Applications for Human LAP (TGF-beta 1) Antibody
Application
Recommended Usage
Immunocytochemistry
5-15 µg/mL
Sample: Immersion fixed human peripheral blood mononuclear cells (PBMCs)
Sample: Immersion fixed human peripheral blood mononuclear cells (PBMCs)
Immunohistochemistry
5-15 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human prostate cancer tissue
Sample: Immersion fixed paraffin-embedded sections of human prostate cancer tissue
Western Blot
1 µg/mL
Sample: Recombinant Human LAP TGF-beta 1 (Catalog # 246-LP)
Sample: Recombinant Human LAP TGF-beta 1 (Catalog # 246-LP)
Neutralization
Measured by its ability to neutralize LAP TGF-beta 1 inhibition of TGF-beta 1 growth inhibition in the HT-2 mouse T cell line. Tsang, M. et al. (1995) Cytokine 7:389. The Neutralization Dose (ND50) is typically 15-30 µg/mL in the presence of 125 ng/mL Recombinant Human LAP TGF-beta 1 and 0.25 ng/mL TGF-beta 1.
Reviewed Applications
Read 1 review rated 5 using AB-246-NA in the following applications:
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Reconstitution
Reconstitute at 1 mg/mL in sterile PBS.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS and NaCl with Trehalose.
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: LAP (TGF-beta 1)
TGF- beta1 (transforming growth factor beta 1) and the closely related TGF-beta 2 and -beta 3 are members of the large TGF-beta superfamily. TGF- beta proteins are highly pleiotropic cytokines that regulate processes such as immune function, proliferation and epithelial-mesenchymal transition (1‑3). Human TGF-beta 1 cDNA encodes a 390 amino acid (aa) precursor that contains a 29 aa signal peptide and a 361 aa proprotein (4). A furin-like convertase processes the proprotein within the trans-Golgi to generate an N-terminal 249 aa (aa 30-278) latency-associated peptide (LAP) and a C-terminal 112 aa (aa 279-390) mature TGF- beta1 (4‑6). Disulfide-linked homodimers of LAP and TGF-beta 1 remain non-covalently associated after secretion, forming the small latent TGF-beta 1 complex (4‑8). Purified LAP is also capable of associating with active TGF-beta with high affinity, and can neutralize TGF-beta activity (9). Covalent linkage of LAP to one of three latent TGF-beta binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix (5‑7). TGF-beta activation from latency is controlled both spatially and temporally, by multiple pathways that include actions of proteases such as plasmin and MMP9, and/or by thrombospondin 1 or selected integrins (5, 8). The LAP portion of human TGF-beta 1 shares 91%, 92%, 85%, 86% and 88% aa identity with porcine, canine, mouse, rat and equine TGF-beta 1 LAP, respectively, while mature human TGF-beta 1 portion shares 100% aa identity with porcine, canine and bovine TGF-beta 1, and 99% aa identity with mouse, rat and equine TGF-beta 1. Although different isoforms of TGF-beta are naturally associated with their own distinct LAPs, the TGF-beta 1 LAP is capable of complexing with, and inactivating, all other human TGF-beta isoforms and those of most other species (9). Mutations within the LAP are associated with Camurati-Engelmann disease, a rare sclerosing bone dysplasia characterized by inappropriate presence of active TGF-beta 1 (10).
References
- Dunker, N. & K. Krieglstein (2000) Eur. J. Biochem. 267:6982.
- Wahl, S.M. (2006) Immunol. Rev. 213:213.
- Chang, H. et al. (2002) Endocr. Rev. 23:787.
- Derynck, R. et al. (1985) Nature 316:701.
- Dabovic, B. and D.B. Rifkin (2008) “TGF-beta Bioavailability” in The TGF-beta Family. Derynck, R. and K. Miyazono (eds): Cold Spring Harbor Laboratory Press, p. 179.
- Brunner, A.M. et al. (1989) J. Biol. Chem. 264:13660.
- Miyazono, K. et al. (1991) EMBO J. 10:1091.
- Oklu, R. and R. Hesketh (2000) Biochem. J. 352:601.
- Miller, D.M. et al. (1992) Mol. Endocrinol. 6:694.
- Janssens, K. et al. (2003) J. Biol. Chem. 278:7718.
Long Name
Latency-associated Peptide
Alternate Names
LAP (TGFbeta 1)
Entrez Gene IDs
7040 (Human)
Gene Symbol
TGFB1
UniProt
Additional LAP (TGF-beta 1) Products
Product Documents for Human LAP (TGF-beta 1) Antibody
Product Specific Notices for Human LAP (TGF-beta 1) Antibody
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...